ADC Therapeutics SA develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors.Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial.
